学术探索
学术期刊
文章热点
数据分析
智能智评

新型口服抗凝药物在非瓣膜性房颤卒中预防中的应用进展

被引：16
作者：
于向东
孙跃民
机构：
[1] 天津医科大学总医院心内科
来源：
中国慢性病预防与控制 | 2015年 / 23卷 / 06期
关键词：
抗凝药物; 心房颤动; 卒中;
D O I：
10.16386/j.cjpccd.issn.1004-6194.2015.06.016
中图分类号：
R541.75 [];
学科分类号：
摘要：
<正>心房颤动(房颤)是临床上最常见的心律失常之一。在美国,房颤在一般人群中患病率超过1%,80岁以上人群超过10%,非瓣膜性房颤可使缺血性卒中发生风险增加4～5倍[1]。我国房颤的患病率约为0.61%,在70岁的非瓣膜性房颤患者中,缺血性脑卒中的发生率为5.3%,房颤住院患者的脑卒中患病率达24.8%,80岁以上患者患病率高达32.9%[2]。过去60年来,维生素K拮抗剂(以华法林为代表)是唯一可用的口服抗凝药
引用
收藏
页码：455 / 459
页数：5
相关论文
共 7 条
  • [1] 中国心房颤动现状的流行病学研究
    周自强
    胡大一
    陈捷
    张仁汉
    李奎宝
    赵秀丽
    [J]. 中华内科杂志, 2004, (07) : 15 - 18
  • [2] Reversal Agents in Development for the New Oral Anticoagulants
    Costin, James
    Ansell, Jack
    Laulicht, Bryan
    Bakhru, Sasha
    Steiner, Solomon
    [J]. POSTGRADUATE MEDICINE, 2014, 126 (07) : 19 - 24
  • [3] Dabigatran, Rivaroxaban, or Apixaban versus Warfarin in Patients with Nonvalvular Atrial Fibrillation: A Systematic Review and Meta-Analysis of Subgroups[J] . Antonio Gómez-Outes,Ana Isabel Terleira-Fernández,Gonzalo Calvo-Rojas,M. Luisa Suárez-Gea,Emilio Vargas-Castrillón,Omer Iqbal.Thrombosis . 2013
  • [4] Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials[J] . Christian T Ruff,Robert P Giugliano,Eugene Braunwald,Elaine B Hoffman,Naveen Deenadayalu,Michael D Ezekowitz,A John Camm,Jeffrey I Weitz,Basil S Lewis,Alexander Parkhomenko,Takeshi Yamashita,Elliott M Antman.The Lancet . 2013
  • [5] Which Oral Anticoagulant for Which Atrial Fibrillation Patient: Recent Clinical Trials and Evidence-Based Choices[J] . John A. Cairns.Canadian Journal of Cardiology . 2013
  • [6] Indirect Comparisons of New Oral Anticoagulant Drugs for Efficacy and Safety When Used for Stroke Prevention in Atrial Fibrillation
    Lip, Gregory Y. H.
    Larsen, Torben Bjerregaard
    Skjoth, Flemming
    Rasmussen, Lars Hvilsted
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2012, 60 (08) : 738 - 746
  • [7] Oral direct thrombin inhibitor AZD0837 for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation: A Phase II study of AZD0837 in patients who are appropriate for but unable or unwilling to take vitamin K antagonist therapy[J] . Thrombosis Research . 2010 (2)
1